Elsheikh, H., Fathy, A., El Sayed, A., Zidan, N., Embaby, A. (2022). Clinical Outcome of Patients with Newly Diagnosed Multiple Myeloma in Zagazig University Hospitals. The Egyptian Journal of Hospital Medicine, 87(1), 2023-2027. doi: 10.21608/ejhm.2022.232248
Haitham Elsheikh; Ayman Fathy; Ahmed Mohamed El Sayed; Nahla I. Zidan; Ahmed Embaby. "Clinical Outcome of Patients with Newly Diagnosed Multiple Myeloma in Zagazig University Hospitals". The Egyptian Journal of Hospital Medicine, 87, 1, 2022, 2023-2027. doi: 10.21608/ejhm.2022.232248
Elsheikh, H., Fathy, A., El Sayed, A., Zidan, N., Embaby, A. (2022). 'Clinical Outcome of Patients with Newly Diagnosed Multiple Myeloma in Zagazig University Hospitals', The Egyptian Journal of Hospital Medicine, 87(1), pp. 2023-2027. doi: 10.21608/ejhm.2022.232248
Elsheikh, H., Fathy, A., El Sayed, A., Zidan, N., Embaby, A. Clinical Outcome of Patients with Newly Diagnosed Multiple Myeloma in Zagazig University Hospitals. The Egyptian Journal of Hospital Medicine, 2022; 87(1): 2023-2027. doi: 10.21608/ejhm.2022.232248
Clinical Outcome of Patients with Newly Diagnosed Multiple Myeloma in Zagazig University Hospitals
Background: Multiple myeloma (MM) is a clonal neoplastic plasma cell disorder. With availability of immunomodulators and bortezomib, better response rate and survival outcome have been achieved in newly diagnosed multiple myeloma (NDMM) patients. Objective: To evaluate patients’ response and outcomes to anti-myeloma treatment in a tertiary referral center. Patients and Methods: From September 2020 to February 2022, at Zagazig University Hospitals, Hematology Unit of Internal Medicine Department, our prospective cohort study was conducted on 36 treatment-naïve patients with NDMM. All patients had received anti-myeloma agents and assessed for response and outcome. Results: About the performance status (PS), one quarter of the cases had PS 0 (25%), and 55.6% of the cases were PS 1. Majority of cases responded to treatment (91.7%), while only three cases did not respond. Thirty-three cases showed no progression (91.7%) and three cases only showed progression (8.3%). Ten patients underwent autologous stem cell transplantation (ASCT). After a median follow-up period of 12 months (range 4-18 months); the OS rate was 76.8%, and PFS rate, was 90.7%. Conclusion: This study highlights that by using proper anti-myeloma agents, a reasonable clinical outcome can be achieved in our tertiary center